The estimated Net Worth of Gisela Paulsen is at least $1.06 Milión dollars as of 15 March 2022. Ms. Paulsen owns over 16,500 units of Exact Sciences stock worth over $1,057,980 and over the last 5 years she sold EXAS stock worth over $0. In addition, she makes $0 as General Manager - Precision Oncology at Exact Sciences.
Gisela has made over 1 trades of the Exact Sciences stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 16,500 units of EXAS stock worth $19,800 on 15 March 2022.
The largest trade she's ever made was buying 16,500 units of Exact Sciences stock on 15 March 2022 worth over $19,800. On average, Gisela trades about 4,125 units every 0 days since 2020. As of 15 March 2022 she still owns at least 16,500 units of Exact Sciences stock.
You can see the complete history of Ms. Paulsen stock trades at the bottom of the page.
Gisela Paulsen serves as General Manager - Precision Oncology of the Company. Prior to joining the Company, Ms. Paulsen served in various management roles at F. Hoffmann-La Roche Ltd. and Genentech, Inc since November 2005. She served as Roche and Genentech's Senior Vice President, Global Head, Product Development, Clinical Operations from January 2018 to April 2020, as Roche and Genentech's Vice President, Global Head, Product Development, Global Product Strategy & Late-Stage Portfolio Finance beginning from March 2017 to February 2018, and as Genentech's Vice President, Access Solutions from September 2014 to February 2017. Ms. Paulsen received a bachelor of science, pharmacy and a master of science, pharmaceutics and drug delivery from Uppsala University in Sweden.
Gisela Paulsen is 54, she's been the General Manager - Precision Oncology of Exact Sciences since 2020. There are 13 older and 9 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
Gisela's mailing address filed with the SEC is 15, Cushing, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania a Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Exact Sciences executives and other stock owners filed with the SEC include: